{"id":5968,"date":"2026-04-01T09:24:29","date_gmt":"2026-04-01T09:24:29","guid":{"rendered":"https:\/\/regenerated.health\/pots-guide\/"},"modified":"2026-07-28T10:04:06","modified_gmt":"2026-07-28T10:04:06","slug":"pots-guide","status":"publish","type":"post","link":"https:\/\/regenerated.com\/blog\/pots-guide\/","title":{"rendered":"POTS (Postural Orthostatic Tachycardia Syndrome): A Complete Guide"},"content":{"rendered":"<div style=\"background:#f0f7f4;border-left:4px solid #2e7d5e;padding:20px 24px;margin-bottom:28px;border-radius:6px;\">\n<h2 style=\"margin-top:0;\">POTS at a Glance<\/h2>\n<ul>\n<li><strong>What it is:<\/strong> A form of dysautonomia where the heart rate increases by 30+ BPM (or exceeds 120 BPM) within 10 minutes of standing, without a significant drop in blood pressure.<\/li>\n<li><strong>Who it affects:<\/strong> Estimated 1-3 million Americans, predominantly women aged 15-50.<\/li>\n<li><strong>Key symptoms:<\/strong> Rapid heartbeat on standing, lightheadedness, brain fog, fatigue, exercise intolerance, and GI dysfunction.<\/li>\n<li><strong>Types:<\/strong> Neuropathic, hyperadrenergic, hypovolemic, and autoimmune.<\/li>\n<li><strong>Common overlaps:<\/strong> EDS (Ehlers-Danlos Syndrome), MCAS (Mast Cell Activation Syndrome), and autoimmune conditions.<\/li>\n<li><strong>Diagnosis:<\/strong> Tilt table test or active standing test with heart rate monitoring.<\/li>\n<li><strong>Treatment:<\/strong> A combination of lifestyle changes, medications, and reconditioning protocols.<\/li>\n<\/ul>\n<\/div>\n<h2>What Is POTS?<\/h2>\n<p>Postural Orthostatic Tachycardia Syndrome, or POTS, is a disorder of the autonomic nervous system. The autonomic nervous system controls involuntary functions like heart rate, blood pressure, digestion, and temperature regulation. When this system malfunctions, the body struggles to adjust to basic positional changes, like going from lying down to standing up.<\/p>\n<p>In a healthy body, standing triggers a coordinated response: blood vessels in the legs constrict, the heart rate increases slightly, and blood pressure remains stable. In POTS, this system breaks down. Blood pools in the lower body, the heart races to compensate, and the brain doesn&#8217;t get the blood flow it needs. The result is a cascade of symptoms that can range from mildly annoying to completely debilitating.<\/p>\n<p>POTS is not simply &#8220;being dizzy when you stand up too fast.&#8221; It is a recognized medical condition with measurable diagnostic criteria. The hallmark is a sustained heart rate increase of 30 beats per minute or more (40 BPM in adolescents) within 10 minutes of standing, without a corresponding drop in blood pressure that would indicate orthostatic hypotension <sup>[1]<\/sup>.<\/p>\n<p>Despite affecting an estimated 1 to 3 million people in the United States alone, POTS remains underdiagnosed. Many patients wait years before receiving an accurate diagnosis, often being told their symptoms are caused by anxiety or deconditioning <sup>[2]<\/sup>.<\/p>\n<h2>Pathophysiology: Why POTS Happens<\/h2>\n<p>POTS is not a single disease. It is better understood as a syndrome with multiple underlying mechanisms. Researchers have identified several subtypes, and many patients have features of more than one.<\/p>\n<h3>Neuropathic POTS<\/h3>\n<p>The most common subtype. In neuropathic POTS, the small nerve fibers that control blood vessel constriction in the lower body are damaged or dysfunctional. When you stand, the blood vessels in your legs and abdomen fail to tighten properly, allowing blood to pool. The heart compensates by beating faster. Small fiber neuropathy can be confirmed through skin punch biopsy and sudomotor testing <sup>[3]<\/sup>.<\/p>\n<h3>Hyperadrenergic POTS<\/h3>\n<p>In this subtype, the body produces excessive amounts of norepinephrine (a stress hormone) upon standing. Patients with hyperadrenergic POTS often have elevated standing norepinephrine levels above 600 pg\/mL and may experience significant blood pressure swings, tremor, and anxiety-like symptoms. This subtype can present with a more pronounced fight-or-flight response and is sometimes associated with mast cell activation <sup>[4]<\/sup>.<\/p>\n<h3>Hypovolemic POTS<\/h3>\n<p>Some POTS patients have abnormally low blood volume, sometimes up to 20% below normal. With less blood circulating, the cardiovascular system struggles to maintain adequate perfusion when gravity pulls blood downward upon standing. The renin-aldosterone system, which regulates blood volume and sodium retention, may be impaired in these patients <sup>[5]<\/sup>.<\/p>\n<h3>Autoimmune POTS<\/h3>\n<p>A growing body of research suggests that autoimmune mechanisms play a role in many POTS cases. Autoantibodies against adrenergic receptors, muscarinic receptors, and ganglionic acetylcholine receptors have been found in subsets of POTS patients. This subtype often follows a viral illness, aligning with the post-infectious onset pattern many patients describe <sup>[6]<\/sup>.<\/p>\n<h2>Symptoms of POTS<\/h2>\n<p>POTS is often called an &#8220;invisible illness&#8221; because patients can look perfectly healthy while experiencing a storm of internal symptoms. The symptom burden is significant. Studies have shown that the quality-of-life impairment in POTS is comparable to that of congestive heart failure and COPD <sup>[7]<\/sup>.<\/p>\n<h3>Cardiovascular Symptoms<\/h3>\n<ul>\n<li>Rapid heartbeat (tachycardia) upon standing, often exceeding 120 BPM<\/li>\n<li>Heart palpitations and chest discomfort<\/li>\n<li>Blood pressure fluctuations<\/li>\n<li>Blood pooling in the legs, causing purplish discoloration (acrocyanosis)<\/li>\n<\/ul>\n<h3>Neurological Symptoms<\/h3>\n<ul>\n<li>Lightheadedness and dizziness<\/li>\n<li>Presyncope (feeling like you are about to faint) and, less commonly, full syncope (fainting)<\/li>\n<li>Brain fog, difficulty concentrating, and memory problems<\/li>\n<li>Headaches, including migraine<\/li>\n<li>Visual disturbances (tunnel vision, blurred vision upon standing)<\/li>\n<\/ul>\n<h3>Systemic Symptoms<\/h3>\n<ul>\n<li>Severe fatigue that is not relieved by rest<\/li>\n<li>Exercise intolerance<\/li>\n<li>Gastrointestinal dysfunction: nausea, bloating, gastroparesis, constipation, or diarrhea<\/li>\n<li>Heat intolerance and excessive or insufficient sweating<\/li>\n<li>Sleep disturbances<\/li>\n<li>Shortness of breath<\/li>\n<li>Tremulousness<\/li>\n<\/ul>\n<p>Symptoms tend to worsen with prolonged standing, heat exposure, after meals (postprandial), during menstrual periods, and during illness. Many patients describe a &#8220;crash&#8221; pattern, where overexertion one day leads to severe symptoms the next.<\/p>\n<h2>How POTS Is Diagnosed<\/h2>\n<p>If you suspect you have POTS, getting an accurate diagnosis is the first critical step. Unfortunately, the average time to diagnosis is still measured in years for many patients.<\/p>\n<h3>Diagnostic Criteria<\/h3>\n<p>The established diagnostic criteria for POTS include <sup>[1]<\/sup>:<\/p>\n<ol>\n<li>A sustained heart rate increase of 30 BPM or more (40 BPM for ages 12-19) within 10 minutes of standing or head-up tilt<\/li>\n<li>Absence of orthostatic hypotension (blood pressure drop of more than 20\/10 mmHg)<\/li>\n<li>Symptoms lasting at least 3 to 6 months<\/li>\n<li>Absence of other conditions that could explain the tachycardia (dehydration, anemia, hyperthyroidism, medication effects)<\/li>\n<\/ol>\n<h3>Tilt Table Test<\/h3>\n<p>The tilt table test is considered the gold standard for POTS diagnosis. You lie flat on a motorized table while heart rate and blood pressure are monitored. The table is then tilted to a 60-70 degree angle to simulate standing, and measurements are taken over 10-45 minutes. This controlled environment allows clinicians to observe the hemodynamic response in real time <sup>[8]<\/sup>.<\/p>\n<h3>Active Standing Test (NASA Lean Test)<\/h3>\n<p>A simpler alternative that can be performed in any doctor&#8217;s office. You lie flat for 5-10 minutes, then stand against a wall (leaning your back for safety) while heart rate and blood pressure are measured at intervals over 10 minutes. This is often called the &#8220;poor man&#8217;s tilt table&#8221; and is widely used as a screening tool <sup>[9]<\/sup>.<\/p>\n<h3>Additional Testing<\/h3>\n<p>Beyond the standing test, a thorough POTS workup may include:<\/p>\n<ul>\n<li>Blood volume testing (though this is not widely available)<\/li>\n<li>Catecholamine levels (supine and standing norepinephrine)<\/li>\n<li>Autoimmune markers and autoantibody panels<\/li>\n<li>Skin punch biopsy for small fiber neuropathy<\/li>\n<li>Sudomotor function testing (QSART)<\/li>\n<li>Blood work to rule out anemia, thyroid dysfunction, and adrenal insufficiency<\/li>\n<li>Echocardiogram and Holter monitor to rule out structural heart issues<\/li>\n<\/ul>\n<h2>Common Triggers and Associations<\/h2>\n<h3>Post-Viral POTS<\/h3>\n<p>Many POTS cases begin after a viral infection. This has been documented following mononucleosis, influenza, and other common viruses for decades. The COVID-19 pandemic brought massive new attention to this pattern, as POTS emerged as one of the most common manifestations of Long COVID. Research suggests that up to 2-14% of COVID-19 survivors may develop POTS or POTS-like symptoms <sup>[10]<\/sup>.<\/p>\n<p>The mechanism behind post-viral POTS may involve autoimmune activation triggered by molecular mimicry, direct viral damage to autonomic nerves, or persistent inflammation affecting the autonomic nervous system.<\/p>\n<h3>The POTS-EDS-MCAS Triad<\/h3>\n<p>There is a well-recognized clinical overlap between POTS, Ehlers-Danlos Syndrome (particularly the hypermobile type), and Mast Cell Activation Syndrome. This triad is so common that clinicians who specialize in one of these conditions routinely screen for the other two <sup>[11]<\/sup>.<\/p>\n<p>In EDS, the lax connective tissue may allow blood vessels to stretch excessively, contributing to blood pooling. MCAS involves inappropriate release of mast cell mediators like histamine, which is a potent vasodilator and can worsen orthostatic symptoms. These three conditions appear to share underlying mechanisms, though the exact nature of their relationship is still being studied.<\/p>\n<h3>Other Associations<\/h3>\n<ul>\n<li>Autoimmune conditions (Sjogren&#8217;s syndrome, lupus, celiac disease)<\/li>\n<li>Chiari malformation and craniocervical instability<\/li>\n<li>Diabetes (especially with autonomic neuropathy)<\/li>\n<li>Pregnancy and hormonal changes<\/li>\n<li>Concussion or traumatic brain injury<\/li>\n<li>Surgery or prolonged bed rest<\/li>\n<\/ul>\n<h2>Conventional Treatments for POTS<\/h2>\n<p>There is no single FDA-approved medication for POTS, so treatment is symptom-based and often involves trial and error. A multimodal approach tends to work best.<\/p>\n<h3>First-Line: Fluid and Salt Loading<\/h3>\n<p>Increasing blood volume is a cornerstone of POTS management. Most POTS specialists recommend:<\/p>\n<ul>\n<li>Drinking 2-3 liters of water daily<\/li>\n<li>Consuming 3-10 grams of sodium per day (far more than the standard dietary recommendation)<\/li>\n<li>Electrolyte beverages or oral rehydration solutions<\/li>\n<\/ul>\n<p>This approach helps increase blood volume and improve venous return to the heart <sup>[12]<\/sup>.<\/p>\n<h3>Compression Garments<\/h3>\n<p>Waist-high compression stockings (30-40 mmHg) or abdominal binders can reduce venous pooling in the legs and abdomen. Knee-high stockings are generally not sufficient because significant pooling occurs in the abdominal vasculature. Some patients find compression leggings more practical for daily wear.<\/p>\n<h3>Medications<\/h3>\n<p><strong>Beta-Blockers:<\/strong> Low-dose propranolol (10-20 mg) is commonly used to blunt the excessive heart rate response. It may also help reduce tremor and anxiety-like symptoms. Higher doses can worsen fatigue and exercise intolerance, so less is often more <sup>[13]<\/sup>.<\/p>\n<p><strong>Midodrine:<\/strong> An alpha-1 agonist that constricts blood vessels, helping to prevent blood pooling. Typically dosed 2.5-10 mg three times daily, with the last dose taken in the afternoon to avoid supine hypertension at night.<\/p>\n<p><strong>Fludrocortisone:<\/strong> A mineralocorticoid that promotes sodium and water retention, expanding blood volume. Used at low doses (0.1-0.2 mg daily). Long-term use requires monitoring of potassium levels and blood pressure.<\/p>\n<p><strong>Ivabradine:<\/strong> A newer option that slows heart rate by acting on the sinus node without affecting blood pressure. Some studies show it may be better tolerated than beta-blockers in POTS patients, particularly those with low blood pressure <sup>[14]<\/sup>.<\/p>\n<p><strong>Pyridostigmine:<\/strong> An acetylcholinesterase inhibitor that improves autonomic ganglionic transmission. It can modestly reduce heart rate and improve symptoms, particularly in the neuropathic subtype. It may also help with GI motility.<\/p>\n<h2>Lifestyle Modifications<\/h2>\n<h3>Exercise Reconditioning: The Levine Protocol<\/h3>\n<p>Exercise is one of the most effective long-term treatments for POTS, but it must be approached carefully. The Modified Dallas\/Levine Protocol is a structured, graduated exercise program designed specifically for POTS patients. It begins with recumbent exercises (recumbent bike, swimming, rowing) to avoid upright posture and gradually introduces upright exercise over 3-6 months <sup>[15]<\/sup>.<\/p>\n<p>Key principles of the Levine Protocol:<\/p>\n<ul>\n<li>Start with recumbent or semi-recumbent exercise only<\/li>\n<li>Begin with short sessions (15-20 minutes) at low intensity<\/li>\n<li>Use heart rate monitoring to stay within target zones<\/li>\n<li>Gradually increase duration before increasing intensity<\/li>\n<li>Add upright exercise only after building a base<\/li>\n<li>Include strength training to build the skeletal muscle pump<\/li>\n<li>Expect 3-6 months before significant improvement<\/li>\n<\/ul>\n<p>Research has shown that a supervised exercise program can reduce resting heart rate, improve orthostatic tolerance, and in some cases reduce the heart rate response to the point where patients no longer meet diagnostic criteria for POTS.<\/p>\n<h3>Sleep Position<\/h3>\n<p>Sleeping with the head of the bed elevated 4-6 inches (using a bed wedge or blocks under the bed legs) can help the body retain more fluid overnight by reducing nighttime diuresis. This simple change can make mornings easier for many POTS patients.<\/p>\n<h3>Cooling Strategies<\/h3>\n<p>Heat is a major trigger for POTS symptoms because it causes vasodilation and worsens blood pooling. Helpful strategies include:<\/p>\n<ul>\n<li>Cooling vests and neck wraps<\/li>\n<li>Cold water consumption before and during heat exposure<\/li>\n<li>Avoiding hot showers (or using a shower chair and keeping the water lukewarm)<\/li>\n<li>Planning outdoor activities for cooler parts of the day<\/li>\n<li>Keeping indoor environments cool<\/li>\n<\/ul>\n<h3>Other Daily Strategies<\/h3>\n<ul>\n<li>Avoid prolonged standing. If you must stand, shift your weight, cross your legs, and contract your calf muscles.<\/li>\n<li>Rise slowly from lying to sitting to standing.<\/li>\n<li>Eat smaller, more frequent meals to avoid postprandial symptom flares.<\/li>\n<li>Reduce refined carbohydrate intake, which can worsen blood pooling after meals.<\/li>\n<li>Avoid alcohol, which causes vasodilation.<\/li>\n<\/ul>\n<h2>Integrative and Emerging Approaches<\/h2>\n<h3>Vagus Nerve Stimulation<\/h3>\n<p>The vagus nerve is a major component of the autonomic nervous system. Non-invasive vagus nerve stimulation (nVNS) devices, such as gammaCore and transcutaneous auricular VNS, are being explored as potential POTS treatments. Early research suggests they may help modulate autonomic tone and reduce symptom burden, though larger studies are needed <sup>[16]<\/sup>.<\/p>\n<h3>IV Fluid Therapy<\/h3>\n<p>For patients with significant hypovolemia or during severe symptom flares, IV saline infusions can provide rapid but temporary relief. Some patients receive regular IV infusions through a port or PICC line. While effective for acute management, the risks of central line infections and the logistical burden mean this approach is typically reserved for refractory cases.<\/p>\n<h3>Low-Dose Naltrexone (LDN)<\/h3>\n<p>LDN (typically 1.5-4.5 mg at bedtime) has gained interest in the POTS community for its immunomodulatory and anti-inflammatory properties. While large-scale POTS-specific trials are lacking, LDN is being used off-label by some clinicians, particularly when autoimmune or inflammatory mechanisms are suspected. It is also used in related conditions like fibromyalgia and ME\/CFS with some supporting evidence <sup>[17]<\/sup>.<\/p>\n<h3>Mast Cell Stabilizers (When MCAS Overlaps)<\/h3>\n<p>For patients with concurrent Mast Cell Activation Syndrome, treating the mast cell component can significantly improve POTS symptoms. Commonly used medications include:<\/p>\n<ul>\n<li>H1 and H2 antihistamines (cetirizine, famotidine)<\/li>\n<li>Cromolyn sodium (a mast cell stabilizer)<\/li>\n<li>Quercetin and luteolin (natural mast cell stabilizers)<\/li>\n<li>Ketotifen<\/li>\n<\/ul>\n<p>Addressing MCAS can reduce the histamine-driven vasodilation that worsens orthostatic intolerance.<\/p>\n<h2>POTS in Teenagers and Adolescents<\/h2>\n<p>POTS frequently develops during adolescence, often around puberty or following a growth spurt. Teenage POTS can be particularly disruptive because it affects school attendance, social activities, and sports participation.<\/p>\n<p>Important considerations for teen POTS:<\/p>\n<ul>\n<li>The diagnostic threshold is higher: 40 BPM increase (rather than 30 BPM) to account for normal adolescent physiology<\/li>\n<li>Deconditioning from missing school and activities can create a vicious cycle<\/li>\n<li>The prognosis is generally better in teens, with many showing significant improvement within 2-5 years<\/li>\n<li>School accommodations (504 plans or IEPs) may be needed, including extra water and bathroom access, ability to sit during activities, flexible attendance policies, and extended time for assignments<\/li>\n<li>The exercise reconditioning approach is especially effective in younger patients<\/li>\n<li>Mental health support is important, as the social impact of chronic illness during formative years can be significant<\/li>\n<\/ul>\n<h2>Prognosis and Recovery<\/h2>\n<p>The outlook for POTS varies significantly depending on the underlying cause, age of onset, and response to treatment.<\/p>\n<p>Some encouraging data points:<\/p>\n<ul>\n<li>Approximately 50-60% of patients with post-viral POTS experience significant improvement within 2-5 years <sup>[18]<\/sup><\/li>\n<li>Adolescent-onset POTS has the best prognosis, with many teens improving substantially by their early twenties<\/li>\n<li>Structured exercise programs can produce lasting improvement in many patients<\/li>\n<li>Patients with identifiable and treatable underlying causes (such as autoimmune POTS responsive to immunotherapy) may see dramatic improvement<\/li>\n<\/ul>\n<p>That said, POTS can be a chronic condition for some patients, particularly those with underlying connective tissue disorders or progressive autonomic neuropathy. Even in chronic cases, most patients can find a combination of treatments that meaningfully improves their quality of life.<\/p>\n<p>Recovery from POTS is rarely linear. Flares and setbacks are normal, especially during illness, hormonal changes, or periods of stress. Pacing, self-compassion, and a long-term view are essential.<\/p>\n<h2>Finding a Dysautonomia Specialist<\/h2>\n<p>One of the biggest challenges POTS patients face is finding a clinician who understands the condition. Here are some strategies:<\/p>\n<ul>\n<li><strong>Dysautonomia International:<\/strong> Maintains a physician directory searchable by location<\/li>\n<li><strong>Academic medical centers:<\/strong> Many major universities have autonomic disorders clinics (Vanderbilt, Mayo Clinic, Cleveland Clinic, Stanford, among others)<\/li>\n<li><strong>Electrophysiologists and autonomic neurologists:<\/strong> These specialists are most likely to have POTS expertise<\/li>\n<li><strong>Patient communities:<\/strong> Online support groups can provide local physician recommendations based on real patient experiences<\/li>\n<li><strong>Telehealth:<\/strong> Some POTS specialists now offer virtual consultations, expanding access for patients in areas without local expertise<\/li>\n<\/ul>\n<p>When choosing a provider, look for someone who takes a systematic approach to identifying your POTS subtype, screens for associated conditions (especially EDS and MCAS), and is willing to try multiple treatments to find what works for you.<\/p>\n<h2>Related Reading<\/h2>\n<ul>\n<li><a href=\"\/blog\/eds-guide\/\">Ehlers-Danlos Syndrome (EDS): A Complete Guide<\/a><\/li>\n<li><a href=\"\/blog\/mcas-guide\/\">Mast Cell Activation Syndrome (MCAS): What You Need to Know<\/a><\/li>\n<li><a href=\"\/blog\/category\/pots\/\">Understanding Dysautonomia: When Your Autonomic Nervous System Misfires<\/a><\/li>\n<li><a href=\"\/blog\/long-covid-guide\/\">Long COVID and Post-Viral Syndromes<\/a><\/li>\n<\/ul>\n<h2>Frequently Asked Questions<\/h2>\n<h3>Is there an FDA-approved medication for POTS?<\/h3>\n<p>No. The guide states there is no single FDA-approved medication for POTS, so treatment often involves trial and error. Commonly used off-label options include beta-blockers such as propranolol (10-20 mg), midodrine (2.5-10 mg three times daily), fludrocortisone (0.1-0.2 mg daily), ivabradine, and pyridostigmine.<\/p>\n<h3>What is the first thing to try for POTS before medication?<\/h3>\n<p>The guide lists first-line non-pharmaceutical steps as drinking 2-3 liters of water daily and consuming 3-10 grams of sodium per day. Other non-drug measures include waist-high compression garments at 30-40 mmHg, elevating the head of the bed 4-6 inches, rising slowly from lying to sitting to standing, and eating smaller, more frequent meals.<\/p>\n<h3>How long does it take to improve with exercise training?<\/h3>\n<p>Using a modified Dallas\/Levine protocol, the guide advises beginning with recumbent or semi-recumbent exercise only and starting with short 15-20 minute sessions at low intensity. It notes that it can take 3-6 months before significant improvement is seen. Recovery is described as rarely linear, with flares and setbacks being normal.<\/p>\n<h3>Can POTS go away, and what is the prognosis?<\/h3>\n<p>For post-viral POTS, the guide states that approximately 50-60% of patients experience significant improvement within 2-5 years. Adolescent-onset POTS has the best prognosis, with many teens improving substantially by their early twenties. However, POTS can be a chronic condition for some patients, particularly those with underlying connective tissue disorders.<\/p>\n<h3>Does COVID-19 cause POTS?<\/h3>\n<p>The guide reports that up to 2-14% of COVID-19 survivors may develop POTS or POTS-like symptoms. This post-viral form often follows a viral illness, and around half to 60% of these patients see significant improvement within 2-5 years.<\/p>\n<h3>Is low-dose naltrexone (LDN) proven for POTS?<\/h3>\n<p>Not conclusively. The guide describes LDN (1.5-4.5 mg at bedtime) as an emerging, off-label approach, and notes that large-scale POTS-specific trials are lacking. It is presented alongside other emerging options such as vagus nerve stimulation, where early research only suggests possible benefit.<\/p>\n<p><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Is there an FDA-approved medication for POTS?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. The guide states there is no single FDA-approved medication for POTS, so treatment often involves trial and error. Commonly used off-label options include beta-blockers such as propranolol (10-20 mg), midodrine (2.5-10 mg three times daily), fludrocortisone (0.1-0.2 mg daily), ivabradine, and pyridostigmine.\"}},{\"@type\":\"Question\",\"name\":\"What is the first thing to try for POTS before medication?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The guide lists first-line non-pharmaceutical steps as drinking 2-3 liters of water daily and consuming 3-10 grams of sodium per day. Other non-drug measures include waist-high compression garments at 30-40 mmHg, elevating the head of the bed 4-6 inches, rising slowly from lying to sitting to standing, and eating smaller, more frequent meals.\"}},{\"@type\":\"Question\",\"name\":\"How long does it take to improve with exercise training?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Using a modified Dallas\/Levine protocol, the guide advises beginning with recumbent or semi-recumbent exercise only and starting with short 15-20 minute sessions at low intensity. It notes that it can take 3-6 months before significant improvement is seen. Recovery is described as rarely linear, with flares and setbacks being normal.\"}},{\"@type\":\"Question\",\"name\":\"Can POTS go away, and what is the prognosis?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"For post-viral POTS, the guide states that approximately 50-60% of patients experience significant improvement within 2-5 years. Adolescent-onset POTS has the best prognosis, with many teens improving substantially by their early twenties. However, POTS can be a chronic condition for some patients, particularly those with underlying connective tissue disorders.\"}},{\"@type\":\"Question\",\"name\":\"Does COVID-19 cause POTS?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The guide reports that up to 2-14% of COVID-19 survivors may develop POTS or POTS-like symptoms. This post-viral form often follows a viral illness, and around half to 60% of these patients see significant improvement within 2-5 years.\"}},{\"@type\":\"Question\",\"name\":\"Is low-dose naltrexone (LDN) proven for POTS?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Not conclusively. The guide describes LDN (1.5-4.5 mg at bedtime) as an emerging, off-label approach, and notes that large-scale POTS-specific trials are lacking. It is presented alongside other emerging options such as vagus nerve stimulation, where early research only suggests possible benefit.\"}}]}<\/script><\/p>\n<h2>References<\/h2>\n<ol>\n<li>Sheldon RS, Grubb BP, Olshansky B, et al. 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome. <em>Heart Rhythm<\/em>. 2015;12(6):e41-e63. <a href=\"https:\/\/doi.org\/10.1016\/j.hrthm.2015.03.029\" target=\"_blank\" rel=\"noopener\">doi:10.1016\/j.hrthm.2015.03.029<\/a><\/li>\n<li>Shaw BH, Stiles LE, Bourne K, et al. The face of postural tachycardia syndrome &#8211; insights from a large cross-sectional online community-based survey. <em>J Intern Med<\/em>. 2019;286(4):438-448. <a href=\"https:\/\/doi.org\/10.1111\/joim.12895\" target=\"_blank\" rel=\"noopener\">doi:10.1111\/joim.12895<\/a><\/li>\n<li>Gibbons CH, Freeman R. Antibody titers predict clinical features of autoimmune autonomic ganglionopathy. <em>Auton Neurosci<\/em>. 2009;146(1-2):8-12. <a href=\"https:\/\/doi.org\/10.1016\/j.autneu.2008.11.013\" target=\"_blank\" rel=\"noopener\">doi:10.1016\/j.autneu.2008.11.013<\/a><\/li>\n<li>Raj SR. Postural tachycardia syndrome (POTS). <em>Circulation<\/em>. 2013;127(23):2336-2342. <a href=\"https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.144501\" target=\"_blank\" rel=\"noopener\">doi:10.1161\/CIRCULATIONAHA.112.144501<\/a><\/li>\n<li>Raj SR, Biaggioni I, Yamhure PC, et al. Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome. <em>Circulation<\/em>. 2005;111(13):1574-1582. <a href=\"https:\/\/doi.org\/10.1161\/01.CIR.0000160356.97313.5D\" target=\"_blank\" rel=\"noopener\">doi:10.1161\/01.CIR.0000160356.97313.5D<\/a><\/li>\n<li>Li H, Yu X, Liles C, et al. Autoimmune basis for postural tachycardia syndrome. <em>J Am Heart Assoc<\/em>. 2014;3(1):e000755. <a href=\"https:\/\/doi.org\/10.1161\/JAHA.113.000755\" target=\"_blank\" rel=\"noopener\">doi:10.1161\/JAHA.113.000755<\/a><\/li>\n<li>Benrud-Larson LM, Dewar MS, Sandroni P, et al. Quality of life in patients with postural tachycardia syndrome. <em>Mayo Clin Proc<\/em>. 2002;77(6):531-537. <a href=\"https:\/\/doi.org\/10.4065\/77.6.531\" target=\"_blank\" rel=\"noopener\">doi:10.4065\/77.6.531<\/a><\/li>\n<li>Low PA, Sandroni P, Joyner M, Shen WK. Postural tachycardia syndrome (POTS). <em>J Cardiovasc Electrophysiol<\/em>. 2009;20(3):352-358. <a href=\"https:\/\/doi.org\/10.1111\/j.1540-8167.2008.01407.x\" target=\"_blank\" rel=\"noopener\">doi:10.1111\/j.1540-8167.2008.01407.x<\/a><\/li>\n<li>Plash WB, Diedrich A, Biaggioni I, et al. Diagnosing postural tachycardia syndrome: comparison of tilt testing compared with standing haemodynamics. <em>Clin Sci (Lond)<\/em>. 2013;124(2):109-114. <a href=\"https:\/\/doi.org\/10.1042\/CS20120276\" target=\"_blank\" rel=\"noopener\">doi:10.1042\/CS20120276<\/a><\/li>\n<li>Johansson M, Stahlberg M, Runold M, et al. Long-haul post-COVID-19 symptoms presenting as a variant of postural orthostatic tachycardia syndrome. <em>JACC Case Rep<\/em>. 2021;3(4):573-580. <a href=\"https:\/\/doi.org\/10.1016\/j.jaccas.2021.01.009\" target=\"_blank\" rel=\"noopener\">doi:10.1016\/j.jaccas.2021.01.009<\/a><\/li>\n<li>Cheung I, Vadas P. A new disease cluster: mast cell activation syndrome, postural orthostatic tachycardia syndrome, and Ehlers-Danlos syndrome. <em>J Allergy Clin Immunol<\/em>. 2015;135(2):AB65. <a href=\"https:\/\/doi.org\/10.1016\/j.jaci.2014.12.1146\" target=\"_blank\" rel=\"noopener\">doi:10.1016\/j.jaci.2014.12.1146<\/a><\/li>\n<li>Garland EM, Celedonio JE, Raj SR. Postural tachycardia syndrome: beyond orthostatic intolerance. <em>Curr Neurol Neurosci Rep<\/em>. 2015;15(9):60. <a href=\"https:\/\/doi.org\/10.1007\/s11910-015-0583-8\" target=\"_blank\" rel=\"noopener\">doi:10.1007\/s11910-015-0583-8<\/a><\/li>\n<li>Raj SR, Black BK, Biaggioni I, et al. Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome. <em>Circulation<\/em>. 2009;120(9):725-734. <a href=\"https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.846501\" target=\"_blank\" rel=\"noopener\">doi:10.1161\/CIRCULATIONAHA.108.846501<\/a><\/li>\n<li>Taub PR, Zadourian A, Lo HC, et al. Randomized trial of ivabradine in patients with hyperadrenergic postural orthostatic tachycardia syndrome. <em>J Am Coll Cardiol<\/em>. 2021;77(7):861-871. <a href=\"https:\/\/doi.org\/10.1016\/j.jacc.2020.12.029\" target=\"_blank\" rel=\"noopener\">doi:10.1016\/j.jacc.2020.12.029<\/a><\/li>\n<li>Fu Q, Vangundy TB, Galbreath MM, et al. Cardiac origins of the postural orthostatic tachycardia syndrome. <em>J Am Coll Cardiol<\/em>. 2010;55(25):2858-2868. <a href=\"https:\/\/doi.org\/10.1016\/j.jacc.2010.02.043\" target=\"_blank\" rel=\"noopener\">doi:10.1016\/j.jacc.2010.02.043<\/a><\/li>\n<li>Brock C, Bagger JP, Mogensen S, et al. Vagal nerve stimulation &#8211; modulation of the anti-inflammatory response and clinical outcome in psoriatic arthritis or ankylosing spondylitis. <em>BMC Rheumatol<\/em>. 2021;5:20. <a href=\"https:\/\/doi.org\/10.1186\/s41927-021-00190-z\" target=\"_blank\" rel=\"noopener\">doi:10.1186\/s41927-021-00190-z<\/a><\/li>\n<li>Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. <em>Clin Rheumatol<\/em>. 2014;33(4):451-459. <a href=\"https:\/\/doi.org\/10.1007\/s10067-014-2517-2\" target=\"_blank\" rel=\"noopener\">doi:10.1007\/s10067-014-2517-2<\/a><\/li>\n<li>Kimpinski K, Figueroa JJ, Singer W, et al. A prospective, 1-year follow-up study of postural tachycardia syndrome. <em>Mayo Clin Proc<\/em>. 2012;87(8):746-752. <a href=\"https:\/\/doi.org\/10.1016\/j.mayocp.2012.02.020\" target=\"_blank\" rel=\"noopener\">doi:10.1016\/j.mayocp.2012.02.020<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Everything you need to know about Postural Orthostatic Tachycardia Syndrome (POTS), a form of dysautonomia causing excessive heart rate increase upon standing. Covers symptoms, diagnosis, types, treatments, and the POTS-EDS-MCAS connection.<\/p>\n","protected":false},"author":1,"featured_media":6288,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","_regenerated_references":"","footnotes":""},"categories":[1012],"tags":[],"class_list":["post-5968","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fatigue-recovery-syndromes"],"_links":{"self":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts\/5968","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/comments?post=5968"}],"version-history":[{"count":3,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts\/5968\/revisions"}],"predecessor-version":[{"id":6954,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts\/5968\/revisions\/6954"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/media\/6288"}],"wp:attachment":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/media?parent=5968"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/categories?post=5968"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/tags?post=5968"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}